

80. (Amended) The method of claim 79, wherein the nucleic acid is encoded by SEQ ID NO: 1.

81. (Amended) The method of claim 79, wherein the nucleic acid is encoded by SEQ ID NO: 3.

82. (Amended) The method of claim 77, wherein the polymorphism results in a decreased level of uridine diphosphate glucuronosyltransferase1A9 (UGT1A9) activity in the patient.

83. (Amended) The method of claim 77, wherein the polymorphism results in a decreased level of uridine diphosphate glucuronosyltransferase1A9 (UGT1A9) expression in the patient.

A2
84. (Amended) The method of claim 77, further comprising identifying a polymorphism in an ATP-binding cassette (ABC) gene.

A3
88. (Amended) A method for evaluating the risk of flavopiridol-induced toxicity in a patient comprising evaluating a ATP-binding cassette (ABC)-encoding nucleic acid of the patient for a polymorphism.

90. (Amended) The method of claim 88, further comprising identifying a polymorphism in a ATP-binding cassette (ABC)-encoding nucleic acid of the patient.

A4
91. (Amended) The method of claim 88, wherein the polymorphism results in a decreased level of ATP-binding cassette (ABC) activity in the patient.

92. (Amended) The method of claim 88, wherein the polymorphism results in a decreased level of ATP-binding cassette (ABC) expression in the patient.